Prothena Corp PLC (PRTA)

55.15
2.12 4.00
NASDAQ : Health Care
Prev Close 53.03
Open 53.84
Day Low/High 51.50 / 55.15
52 Wk Low/High 28.20 / 76.42
Volume 347.68K
Avg Volume 267.10K
Exchange NASDAQ
Shares Outstanding 38.02M
Market Cap 2.19B
EPS -4.70
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

3 Stocks You Probably Never Heard Of Could Catch Fire Soon

3 Stocks You Probably Never Heard Of Could Catch Fire Soon

Prothena Announces Appointment Of Wagner Zago, PhD As Chief Scientific Officer

Prothena Announces Appointment Of Sarah Noonberg, MD, PhD As Chief Medical Officer

Prothena Reports First Quarter 2017 Financial Results And Provides R&D Update

Prothena To Report First Quarter 2017 Financial Results On May 9

Prothena To Participate In The Deutsche Bank 42nd Annual Health Care Conference

Clinical Results Presented From Prothena's Phase 1b Study Of PRX002/RG7935 Demonstrating Robust Antibody CNS Penetration And Significant Reduction Of Free Serum Alpha-synuclein In Patients With Parkinson's Disease

Results For Prothena's Phase 1b Multiple Ascending Dose Study Of PRX002/RG7935 In Patients With Parkinson's Disease To Be Presented At The 13th¿ International Conference On Alzheimer's And Parkinson's Diseases

Prothena Raises $155.3M to Bring Anti-Organ Failure Drug to Market

Prothena Raises $155.3M to Bring Anti-Organ Failure Drug to Market

The biotech company plans to commercialize its treatment for AL amyloidosis, a disease that causes protein to build up in the blood.

Biotech Premarket Movers: Karyopharm, Lexicon, Prothena

Biotech Premarket Movers: Karyopharm, Lexicon, Prothena

Karyopharm Therapeutics falls 18%; Lexicon rises on drug approval.

Prothena Announces Pricing Of Public Offering Of 2,700,000 Ordinary Shares

Prothena Announces Public Offering Of Ordinary Shares

Prothena Reports Fourth Quarter And Full Year 2016 Financial Results, And Provides Financial Guidance And R&D Update

Prothena To Participate In The Leerink Partners 6th Annual Global Healthcare Conference

Prothena To Report Fourth Quarter And Full Year 2016 Financial Results And Host Webcast Conference Call On February 14

Prothena To Participate In The J.P. Morgan Healthcare Conference

Prothena To Participate In The J.P. Morgan Healthcare Conference

Prothena Announces Appointment Of Chief Regulatory Officer

Prothena Announces Appointment Of Chief Regulatory Officer

First-In-Human Assessment Of PRX002, Prothena's Anti-Alpha Synuclein Antibody For Parkinson's Disease, Published In Movement Disorders Journal

First-In-Human Assessment Of PRX002, Prothena's Anti-Alpha Synuclein Antibody For Parkinson's Disease, Published In Movement Disorders Journal

Data Previously Presented in 2015 at 19th International Congress of Parkinson's Disease and Movement Disorders

Prothena Reports Results From Phase 1b Study Of PRX002 Demonstrating Robust Antibody CNS Penetration And Significant Reduction Of Free Serum Alpha-synuclein In Patients With Parkinson's Disease

Prothena Reports Results From Phase 1b Study Of PRX002 Demonstrating Robust Antibody CNS Penetration And Significant Reduction Of Free Serum Alpha-synuclein In Patients With Parkinson's Disease

Data For Prothena's NEOD001 To Be Presented At The 58th Annual American Society Of Hematology Meeting

Data For Prothena's NEOD001 To Be Presented At The 58th Annual American Society Of Hematology Meeting

Prothena Reports Third Quarter 2016 Financial Results And Provides R&D Update

Prothena Reports Third Quarter 2016 Financial Results And Provides R&D Update

Prothena To Report Third Quarter 2016 Financial Results On November 1

Prothena To Report Third Quarter 2016 Financial Results On November 1

Prothena Announces Appointment Of Dr. Gene G. Kinney As President, Chief Executive Officer And Director

Prothena Announces Appointment Of Dr. Gene G. Kinney As President, Chief Executive Officer And Director

In Memoriam - Friend, Scientific Innovator And Leader Dr. Dale B. Schenk Has Passed Away

In Memoriam - Friend, Scientific Innovator And Leader Dr. Dale B. Schenk Has Passed Away

Prothena Outlines Phase 2 Development Strategy For PRX003

Prothena Outlines Phase 2 Development Strategy For PRX003

Prothena Announces President And CEO Dr. Dale B. Schenk To Take Medical Leave

Prothena Announces President And CEO Dr. Dale B. Schenk To Take Medical Leave

Prothena To Host Update On PRX003 Phase 2 Development Strategy

Prothena To Host Update On PRX003 Phase 2 Development Strategy

Prothena Announces Appointment Of Gene G. Kinney As Chief Operating Officer

Prothena Announces Appointment Of Gene G. Kinney As Chief Operating Officer

Prothena To Participate In Upcoming September Investor Conferences

Prothena To Participate In Upcoming September Investor Conferences

Prothena Reports Second Quarter 2016 Financial Results; Provides R&D Update

Prothena Reports Second Quarter 2016 Financial Results; Provides R&D Update

Load More
Quant Rating on 4:00 PM EDT 6/28/2017

D

(Sell)

From Our Partners

Premarket analyst action - healthcare
SeekingAlpha

Prothena initiated with a Buy at BTIG
The Fly

New medical chief at Prothena
SeekingAlpha

Safety concerns with Ionis' inotersen makes Prothena worth a look - Piper
SeekingAlpha

Piper Jaffray sees positive readthrough for Prothena from Ionis data
The Fly

Prothena has positive read through from Ionis safety issues, says SunTrust
The Fly

Prothena EPS of -$0.99
SeekingAlpha

Notable earnings after Tuesday’s close
SeekingAlpha

Prothena initiated with an Overweight at Cantor
The Fly

Prothena initiated with an Overweight at Piper Jaffray
The Fly

Prothena (PRTA) Clinical Results from Phase 1b MAD Study of PRX002/RG7935 in Patients with Parkinson's Disease - Slideshow
SeekingAlpha

Prothena prices equity offering; shares down 4% premarket
SeekingAlpha

Prothena readies 2.7M-share equity offering; shares ease a fraction after hours
SeekingAlpha

Premarket analyst action - healthcare
SeekingAlpha

Prothena initiated with a Buy at Nomura
The Fly
TheStreet Quant Rating: D (Sell)

Get the (PRTA)
Report Here

Trending
The 14 Worst Cruise Ships on the CDC's Sanitary Inspection List
We Sent a Millennial to a Decaying Kmart Store and Couldn't Believe the Horrors She Discovered
11 Cruise Lines With the Cleanest Ships
5 of the Worst Cruise Ships According to the CDC's Sanitary Inspection List
Fund Managers Are Telling You to Buy More Apple and Facebook